Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
A Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
Sponsor: Hospital de Clinicas de Porto Alegre
Listed as NCT03632213, this PHASE2 trial focuses on MPS - Mucopolysaccharidosis and MPS IV A and remains ongoing. Sponsored by Hospital de Clinicas de Porto Alegre, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2019 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital de Clinicas de Porto Alegre
- The Isaac Foundation
For direct contact, visit the study record on ClinicalTrials.gov .